# A Case of Fournier's Gangrene Following the Initiation of Dapagliflozin

## TL;DR

A 66-year-old man developed Fournier's gangrene, a rare and severe infection, after starting dapagliflozin, a diabetes medication.

## Contribution

This case report highlights Fournier's gangrene as a rare but serious adverse effect of dapagliflozin.

## Key findings

- A 66-year-old man developed Fournier’s gangrene shortly after initiating dapagliflozin.
- Fournier’s gangrene is a rare but dangerous adverse effect associated with SGLT2 inhibitors like dapagliflozin.

## Abstract

Since being approved by the United States Food and Drug Administration (FDA) in 2013, sodium-glucose cotransporter-2 inhibitors (SGLT2is) have emerged as an appealing therapeutic choice for patients with diabetes due to their favorable effects on renal and cardiac health. Recent trials have further expanded the application of these drugs by showing a decrease in mortality rates among patients with both reduced and preserved ejection fraction heart failure, even in those without diabetes. Common adverse effects of SGLT2is include increased urinary frequency and urinary tract infections stemming from elevated glycosuria. Here, we present a case report involving a 66-year-old man who developed Fournier’s gangrene (FG) shortly after initiating dapagliflozin - a rare but dangerous adverse effect associated with this medication.